Robert Doebele - 03 Feb 2025 Form 4 Insider Report for Boundless Bio, Inc. (BOLD)

Reporting relationship: Chief Medical Officer
Issuer ticker: BOLD
Reported as of: 03 Feb 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Feb 2025, 18:38:53 UTC
Prior SEC filing: 26 Jan 2024
Next SEC filing: 26 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Jessica Oien, Attorney-in- Fact for Robert Doebele.

Key filing fact

Robert Doebele filed Form 4 for Boundless Bio, Inc. (BOLD) on 03 Feb 2025.

Key facts

This page summarizes Robert Doebele's Form 4 filing for Boundless Bio, Inc. (BOLD).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Feb 2025, 18:38.

Change

Previous filing in this sequence was filed on 26 Jan 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BOLD transaction Derivative

Stock Option

Award

Transaction value: $0
Shares: +180,000
Change %
Price: $0.000000
Shares after: 180,000
Date: 03 Feb 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 180,000
Exercise price: $2.23
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option shall vest over a period of four years, with 25% of the shares subject to the option vesting on February 3, 2026, and the remaining shares subject to the option vesting in 36 equal monthly installments thereafter, subject to continued employment or service to the issuer on each such vesting date.